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ALL-TRANS RETINOIC ACID INDUCED THROMBOCYTOSIS  
IN A PATIENT W ITH ACUTE PROMYELOCYTIC LEUKAEMIA
We read with interest the paper by Losada at al (1996) 
reporting two cases of severe thrombocytosis occurring in 
patients with acute promyelocytic leukaemia (APL) during 
all-iraNA’ retinoic acid (ATRA) treatment. Toxicities of ATRA 
are multiple; they include dryness of the skin and mucous 
membranes, cheilosis, headache, hypertriglyceridaemia, 
bone pain, and pseudotumour cerebri. Two life-threatening 
side-effects have been reported: hyperleucocytosis >20 x 
109/1 occurring in 25% of patients, and retinoic acid 
syndrome characterized by fever, respiratory distress, heart 
failure, pulmonary infiltrates, pleuropericardial effusions 
and oedema. We present the case of a patient with a similar 
history of severe thrombocytosis occurring during treatment 
with ATRA for APL.
In December 1995 a 4 9 -year-old patient presented with a 
2-month history of progressive asthenia followed by spon­
taneous cutaneous haemorrhages. Laboratory blood tests at 
presentation were: WBC 1-8 x 109/1 (PMN 18%, lympho­
cytes 34%, monocytes 7%, eosinophils 3%, metamyelocytes 
11%, myelocytes 16%, promyelocytes 8%, blasts 3%, 
erythroblasts 3%), haemoglobin 7*6 g/dl, platelets 
1 6 x 1 0  /1. Disseminated intravascular coagulation was 
present. APL was diagnosed by bone marrow examination 
which showed 23-7% of abnormal promyelocytic blasts. 
Cytogenetic studies disclosed the presence of the chromo­
somal translocation t(15;17). The patient was given ATRA 
4 5 mg/m~/d orally, combined with idarubicin every 2 d for 
8 d according to the GIMEMA-AIEOP AIDA protocol 
(Avvisati et al, 1996). On day 7 the patient complained of 
headache and blurred vision. An eye fundus disclosed a 
bilateral papiloedema without retinal haemorrhage. As the 
brain computed tomography was normal, the diagnosis of 
pseudotumour cerebri was considered to be very probable 
and treatment with ATRA was interrupted. After recovery of 
normal vision and disappearance of headaches, ATRA was 
re-administered on day 12 without further side-eflect. On 
day 29, BM examination was normal but all criteria of 
complete remission were not obtained in the peripheral blood 
(WBC count 6-6 x 109/1, platelets 179 x 109/1, butHb 8-2 g/ 
dl). It was planned according to the protocol to continue 
ATRA alone until day 60. On day 42, laboratory blood tests 
disclosed a significant thrombocytosis with a platelet count 
of 1071 x 10tJ/l. No obvious cause of thrombocytosis, for 
example no signs of infection, or chronic inflammatory 
syndrome, or haemorrhage, or haemolytic anaemia could be 
found (Williams, 1995). The only other medication, in 
addition to ATRA, administered at that time was insulin. 
ATRA was thought to be a potential cause of the 
thrombocytosis and was interrupted. The platelet count
decreased to 9 6 0 x 1C)9/I after 2d  and reached normal 
values on day 56. Complete remission was obtained at day 
60. Three consolidation courses were then completed. As no 
minimal residual disease at the molecular level could be 
demonstrated, the patient was randomized to sequential 
maintenance treatment with 6MP, MTX and ATRA.
During maintenance treatment with ATRA (45 mg/m /d 
for 15 d), no recurrence of the thrombocytosis was observed. 
14 months alter the beginning of therapy, the patient is 
perfectly well.
The close temporal correlation between the administra­
tion of ATRA and the occurrence of the thrombocytosis and 
its prompt disappearance after the interruption of therapy 
suggest that the side-effect was due to ATRA.
As reported by Losada e£ al (1996), severe thrombocytosis 
is a potential side-effect of ATRA in APL.
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